|1.||Saravanan, G: 3 articles (05/2003 - 01/2002)|
|2.||Pari, L: 3 articles (05/2003 - 01/2002)|
|3.||Venkateswaran, S: 1 article (11/2002)|
|4.||Kumar, Prem: 1 article (08/2002)|
|5.||Achike, Francis I: 1 article (08/2002)|
|6.||Hashim, Rohaini: 1 article (08/2002)|
|7.||Kaur, Gurpreet: 1 article (08/2002)|
|8.||Shekhar, K Chandra: 1 article (08/2002)|
|9.||Mal'tsev, G Iu: 1 article (01/2002)|
|10.||Vasil'ev, A V: 1 article (01/2002)|
|1.||Type 2 Diabetes Mellitus (MODY)
08/01/2002 - "These results concur with earlier animal studies that indicate that Cogent db is safe, reliable, tolerable, and efficacious in the control of type 2 diabetes mellitus."
01/01/2002 - "The scheme of investigation of efficacy of food dietary supplements in complex treatment of patients with diabetes mellitus type 2 associated with obesity was offered on basis of study of influence "Cogent DB+" on mechanisms of metabolic disorders in these patients."
05/01/2003 - "Thus our study shows that Cogent db exhibits a strong antihyperlipidaemic effect, which could exert a beneficial action against macrovascular complications (cardiovascular disease) associated with diabetes mellitus."
01/01/2002 - "Antidiabetic effect of Cogent db, a herbal drug in alloxan-induced diabetes mellitus."
|4.||Cardiovascular Diseases (Cardiovascular Disease)
|5.||Body Weight (Weight, Body)
11/01/2002 - "In the experiment, six rats were used in each group: Group 1, normal rats given 2 ml of saline; Group 2, diabetic control rats given 2 ml of saline; Group 3, diabetic rats given aqueous solution of cogent db (0.45 g/body kg weight); and Group 4, diabetic rats given aqueous solution of glibenclamide (600 micro g/kg body weight). "
05/01/2003 - "The rats were divided into four groups after the induction of alloxan diabetes: normal rats; diabetic control; diabetic rats given Cogent db (0.45 g/kg body weight); diabetic rats given glibenclamide (600 micro g/kg body weight). "